WallStreetZenWallStreetZen

NASDAQ: PGNY
Progyny Inc Stock

$28.95+0.77 (+2.73%)
Updated Jul 12, 2024
PGNY Price
$28.95
Fair Value Price
$65.54
Market Cap
$2.76B
52 Week Low
$23.90
52 Week High
$44.95
P/E
44.54x
P/B
4.82x
P/S
3.32x
PEG
2.91x
Dividend Yield
N/A
Revenue
$1.11B
Earnings
$61.26M
Gross Margin
21.9%
Operating Margin
6.66%
Profit Margin
5.5%
Debt to Equity
0.39
Operating Cash Flow
$194M
Beta
1.37
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PGNY Overview

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PGNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PGNY ($28.95) is undervalued by 55.83% relative to our estimate of its Fair Value price of $65.54 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PGNY ($28.95) is significantly undervalued by 55.83% relative to our estimate of its Fair Value price of $65.54 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PGNY ($28.95) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PGNY due diligence checks available for Premium users.

Be the first to know about important PGNY news, forecast changes, insider trades & much more!

PGNY News

Valuation

PGNY fair value

Fair Value of PGNY stock based on Discounted Cash Flow (DCF)
Price
$28.95
Fair Value
$65.54
Undervalued by
55.83%
PGNY ($28.95) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PGNY ($28.95) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PGNY ($28.95) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PGNY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
44.54x
Industry
2.28x
Market
32.2x
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

PGNY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.82x
Industry
2.95x
PGNY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PGNY price to earnings growth (PEG)

For valuing profitable companies with growth potential
PGNY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

PGNY's financial health

Profit margin

Revenue
$278.1M
Net Income
$16.9M
Profit Margin
6.1%
PGNY's Earnings (EBIT) of $73.76M... subscribe to Premium to read more.
Interest Coverage Financials
PGNY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$794.3M
Liabilities
$222.7M
Debt to equity
0.39
PGNY's short-term assets ($681.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PGNY's short-term assets ($681.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PGNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$25.7M
Investing
$19.3M
Financing
-$27.4M
PGNY's operating cash flow ($193.59M)... subscribe to Premium to read more.
Debt Coverage Financials

PGNY vs Health Information Service Stocks

TickerMarket Cap1d %P/EP/B
PGNY$2.76B+2.73%44.54x4.82x
GDRX$2.89B-3.99%-771.00x4.58x
CERT$2.44B+0.40%-38.92x2.32x
EVH$2.29B+0.36%-15.63x1.86x
PRVA$2.14B0.00%105.41x3.71x

Progyny Stock FAQ

What is Progyny's quote symbol?

(NASDAQ: PGNY) Progyny trades on the NASDAQ under the ticker symbol PGNY. Progyny stock quotes can also be displayed as NASDAQ: PGNY.

If you're new to stock investing, here's how to buy Progyny stock.

What is the 52 week high and low for Progyny (NASDAQ: PGNY)?

(NASDAQ: PGNY) Progyny's 52-week high was $44.95, and its 52-week low was $23.90. It is currently -35.6% from its 52-week high and 21.13% from its 52-week low.

How much is Progyny stock worth today?

(NASDAQ: PGNY) Progyny currently has 95,220,688 outstanding shares. With Progyny stock trading at $28.95 per share, the total value of Progyny stock (market capitalization) is $2.76B.

Progyny stock was originally listed at a price of $15.94 in Oct 25, 2019. If you had invested in Progyny stock at $15.94, your return over the last 4 years would have been 81.62%, for an annualized return of 16.09% (not including any dividends or dividend reinvestments).

How much is Progyny's stock price per share?

(NASDAQ: PGNY) Progyny stock price per share is $28.95 today (as of Jul 12, 2024).

What is Progyny's Market Cap?

(NASDAQ: PGNY) Progyny's market cap is $2.76B, as of Jul 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Progyny's market cap is calculated by multiplying PGNY's current stock price of $28.95 by PGNY's total outstanding shares of 95,220,688.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.